{"id":"NCT00252720","sponsor":"AstraZeneca","briefTitle":"DIabetic Retinopathy Candesartan Trials.","officialTitle":"DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-08","primaryCompletion":"2008-02","completion":"2008-04","firstPosted":"2005-11-15","resultsPosted":"2014-06-03","lastUpdate":"2014-06-03"},"enrollment":1850,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes"],"interventions":[{"type":"DRUG","name":"candesartan","otherNames":["ATACAND"]}],"arms":[{"label":"candesartan","type":"EXPERIMENTAL"},{"label":"placebo","type":"NO_INTERVENTION"}],"summary":"The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.\n\nThe secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate of change in urinary albumin excretion rate (UAER).\n\nThis study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.","primaryOutcome":{"measure":"Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale","timeFrame":"From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.","effectByArm":[{"arm":"Candesartan","deltaMin":127,"sd":0.034},{"arm":"Placebo","deltaMin":124,"sd":0.033}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8487"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["38682786","21309844","21225239","19451554","18823656"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1268&filename=CSR-D2453C00046.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1268&filename=CSR-D2453C00046.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":173,"n":951},"commonTop":["Hypotension"]}}